Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck RotaTeq by Quarter
RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide sales ($M) ($M)
Merck RotaTeq: $134M in Q2 2026, up 10.7% from a year earlier.
Latest, Q2 2026
134
Period ended Jun 30, 2026
Change on a year earlier
+10.7%
121 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
10
Documents cited below
Where the Q2 2026 figure comes from
“|| RotaTeq | 134 | 121 | 10 | 84 | 60 | 39 | 50 | 61 | -18”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up rotaTeq
- RotaTeq (rotavirus live oral pentavalent vaccine) — U.S. sales ($M)84 · Q2 2026
- RotaTeq (rotavirus live oral pentavalent vaccine) — International sales ($M)50 · Q2 2026
- RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide reported growth YoY (%)10.0% · Q2 2026
- RotaTeq (rotavirus live oral pentavalent vaccine) — Worldwide constant-currency (ex-exchange) growth YoY (%)9.0% · Q2 2026
Cite this data
StockData. (2026). Merck RotaTeq ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-rotateq
See every metric in the Merck KPI table. Data updated Oct 26, 2026.